Refine by
Patient Selection Articles & Analysis
69 news found
SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to identify patients with ecDNA amplified tumors using the SOPHiA DDM™ Platform. ...
JUNE Medical is delighted to announce a new agreement with a major US hospital group to supply the award-winning Galaxy II® self-retaining surgical retractors to over 1,600 hospitals in the US, commencing April 15, 2023. This game-changing device radically improves the safety and ease of surgical retraction for both patients and medical staff; its ergonomic design transforms the way in which ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
Treatment-emergent AEs led to dose reductions in 16 patients (31.4%) and to dose interruptions in 33 patients (64.7%). Seven patients (13.7%) discontinued treatment due to AEs. ...
“With darolutamide’s unprecedented survival data and minimal disruption to patients´ daily living across both mHSPC and high risk nmCRPC, following regulatory approval, we will be working to ensure that as many patients as possible benefit from darolutamide. ...
ByBayer AG
” Cellworks Precision Drug Development: Clinical Stage Clinical Trial Biosimulation: By biosimulating clinical trials, the Cellworks Platform may be able to predict human clinical response to pharmaceutical agents in just weeks, delivering critical insights years ahead of a traditional clinical trial. Patient cohorts are selected from the Cellworks ...
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...
MedAxiom, with the support of Daxor, recently completed a project to identify best practices to build a blueprint of how to operationalize BVA through a care pathway that focuses on everything from patient selection to monitoring, and operationally from strategy to billing. ...
” Significant mitral regurgitation prevalence rates are estimated to be up to 10% to 25% in patients in their seventies. During the procedure, operators implant one or more clips onto the valve leaflets with real-time echocardiographic imaging. Clinical data suggests MitraClip helps improve symptoms and survival in appropriately selected ...
“Glioblastoma remains one of the most aggressive and difficult to treat cancers globally and we believe that targeted radiotherapy and particularly ITM-31 can make a significant impact for patients by selectively eliminating tumor remnants post-surgery,” said Steffen Schuster, CEO of ITM. ...
25 European companies from the Biotech, Medtech, Innovative Services & Digital Health sectors, committed to patients, selected by the European clusters, will present their innovation to a jury composed of HTFC’s sponsors and the HTID health innovation ecosystem. The HealthTech Innovation Days (HTID®) event, organized by the HealthTech For Care ...
Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that dosing has commenced in its Phase 2 study — a multi-center ...
“In contrast to population-based therapy guidelines, the Cellworks Biosimulation Platform produces personalized therapy predictions for each NSCLC patient based on a patient-specific multi-omic disease model. The myCare-203A study found that the personalized approach of Cellworks SingulaTM TRI produces a more precise therapeutic decision guide for ...
“This approval reaffirms Bayer’s commitment to patients across different stages of prostate cancer, providing these eligible patients with a reliable treatment ...
ByBayer AG
This electrical activity, which is measurable by EEG as epileptiform discharges, may generate a vicious cycle leading to accelerated cell death and deterioration for some patients. Beacon Biosignals developed a machine learning algorithm trained to detect such epileptiform activity in patients with Alzheimer's. ...
” Xilis’ proprietary tumorsphere microencapsulation platform evaluates cancer therapies at scale and is designed to enable physicians to make precision oncology treatment decisions, identifying treatments that will led to the best response for each patient. Alain Kummer, Managing Director Oncode Institute and Chairman of Oncode-PACT, explains: “Oncode-PACT ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. ...
The SeptiScore®, as evaluated by SeptiCyte® RAPID, of critical and severe patients in the ICU was higher relative to the moderate and mild cases not in ICU. Also, the utility of the SeptiScore® for longitudinal monitoring of patients with severe cases was suggested by repeat testing on selected patients. ...